Anti-IGF-I receptor antibody

Number of patents in Portfolio can not be more than 2000

United States of America Patent

SERIAL NO

10897406

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to, and inhibit, insulin-like growth factor-I receptor, antagonize the effects of IGF-I, IGF-II and serum on the growth and survival of tumor cells, and which are substantially devoid of agonist activity. Said antibodies and fragments thereof may be used, optionally in conjunction with other therapeutic agents, in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma, prostate cancer and pancreatic cancer, and said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of IGF-I receptor.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
IMMUNOGEN INC830 WINTER STREET WALTHAM MA 02451

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Dagdigian, Nancy E Acton, MA 9 231
Singh, Rajeeva Cambridge, MA 33 735
Tavares, Daniel J Natick, MA 23 321

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation